Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Retinal Vascular Density as A Novel Biomarker of Acute Renal Injury after Acute Coronary Syndrome.

Alan G, Guenancia C, Arnould L, Azemar A, Pitois S, Maza M, Bichat F, Zeller M, Gabrielle PH, Bron AM, Creuzot-Garcher C, Cottin Y.

Sci Rep. 2019 May 30;9(1):8060. doi: 10.1038/s41598-019-44647-9.

2.

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B.

Contrast Media Mol Imaging. 2018 Dec 2;2018:8494031. doi: 10.1155/2018/8494031. eCollection 2018.

3.

The EYE-MI Pilot Study: A Prospective Acute Coronary Syndrome Cohort Evaluated With Retinal Optical Coherence Tomography Angiography.

Arnould L, Guenancia C, Azemar A, Alan G, Pitois S, Bichat F, Zeller M, Gabrielle PH, Bron AM, Creuzot-Garcher C, Cottin Y.

Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4299-4306. doi: 10.1167/iovs.18-24090.

PMID:
30372758
4.

Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.

Ubink R, Dirksen EHC, Rouwette M, Bos ES, Janssen I, Egging DF, Loosveld EM, van Achterberg TA, Berentsen K, van der Lee MMC, Bichat F, Raguin O, van der Vleuten MAJ, Groothuis PG, Dokter WHA.

Mol Cancer Ther. 2018 Nov;17(11):2389-2398. doi: 10.1158/1535-7163.MCT-18-0329. Epub 2018 Aug 9.

PMID:
30093567
5.

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.

Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, Rekdal Ø.

J Med Chem. 2016 Apr 14;59(7):2918-27. doi: 10.1021/acs.jmedchem.5b02025. Epub 2016 Mar 29.

PMID:
26982623
6.

High levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction.

Lorin J, Guilland JC, Korandji C, Touzery C, Bichat F, Chagnon A, Cottin Y, Rochette L, Vergely C, Zeller M.

PLoS One. 2013 Jun 6;8(6):e64796. doi: 10.1371/journal.pone.0064796. Print 2013.

7.

Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.

Nguyen TA, Tychopoulos M, Bichat F, Zimmermann C, Flinois JP, Diry M, Ahlberg E, Delaforge M, Corcos L, Beaune P, Dansette P, André F, de Waziers I.

Mol Pharmacol. 2008 Apr;73(4):1122-33. doi: 10.1124/mol.107.042861. Epub 2008 Jan 22. Erratum in: Mol Pharmacol. 2008 Jun;73(6):1866.

PMID:
18212249
8.

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.

Cancer Res. 2006 Sep 15;66(18):9134-42.

9.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC.

Mol Cancer Ther. 2005 Apr;4(4):641-9.

10.

Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.

Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo JL, Bichat F, Rat P, Genne P, Benoit L.

Surg Oncol Clin N Am. 2003 Jul;12(3):835-48. Review.

PMID:
14567035
11.
12.

[Preclinical evaluation of aromatase inhibitors antitumor activity].

Auvray P, Bichat F, Genne P.

Bull Cancer. 2000 Dec;87 Spec No:7-22. Review. French.

PMID:
11250604
13.

Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells.

Droin N, Bichat F, Rébé C, Wotawa A, Sordet O, Hammann A, Bertrand R, Solary E.

Blood. 2001 Mar 15;97(6):1835-44.

14.

S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells.

Bichat F, Solis-Recendez G, Poullain MG, Poupon MF, Khayat D, Bastian G.

Biochem Pharmacol. 1998 Aug 15;56(4):497-502.

PMID:
9763226
15.

Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.

Canitrot Y, Bichat F, Cole SP, Deeley RG, Gerlach JH, Bastian G, Arvelo F, Poupon MF.

Cancer Lett. 1998 Aug 14;130(1-2):133-41.

PMID:
9751266
16.

Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line.

Bichat F, Mouawad R, Solis-Recendez G, Khayat D, Bastian G.

Anticancer Res. 1997 Sep-Oct;17(5A):3393-401.

PMID:
9413178
17.

Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.

Arvelo F, Poupon MF, Bichat F, Grossin F, Bourgeois Y, Jacrot M, Bastian G, Le Chevalier T.

Eur J Cancer. 1995 Oct;31A(11):1862-8.

PMID:
8541114

Supplemental Content

Loading ...
Support Center